Biora Therapeutics Home
Activate the mobile navigation
Close the mobile navigation Close
Home
  • Company
    • About
    • Leadership
    • Careers
  • Pipeline
    • Development Pipeline
    • Targeted Therapeutics
    • Systemic Therapeutics
  • Publications
  • Investors
    • Investor Overview
    • Press Releases
    • Events & Presentations
    • SEC Filings
    • Annual & Quarterly Reports
    • Stock Quote & Chart
    • Historical Price Lookup
    • Analyst Coverage
    • Governance Documents
    • Committee Composition
    • Investor FAQs
    • Investor Email Alerts
    • Investor Relations Contact
  • Contact
Toggle the search bar
Close the mobile navigation

Publications

Evaluation of the pharmacokinetics of glucagon-like-peptide-1 (GLP-1) receptor agonist delivered through the BioJetâ„¢ oral biotherapeutic delivery platform in a porcine model
June 23, 2023 #Systemic Therapeutics
Evaluation of the pharmacokinetics of PGN-OB1 following oral administration of an oral biotherapeutics delivery system (OBDS) in Yucatan swine
October 23, 2022 #Systemic Therapeutics
Development of ex-vivo and in-vivo models to assess the performance of an oral biotherapeutic delivery system (OBDS) capsule
October 23, 2022 #Systemic Therapeutics
Development of preclinical models to assess the performance of the oral biotherapeutic delivery system (OBDS) capsule
October 18, 2022 #Systemic Therapeutics

Connect with us

Email Us Biora Therapeutics Linkedin Biora Therapeutics Twitter
  • Company

    About Leadership Careers

    Pipeline

    Development Pipeline Targeted Therapeutics Systemic Therapeutics
  • Publications

    Targeted Therapeutics Systemic Therapeutics Gastrointestinal Health

    Investors

    Investor Overview Press Releases Events & Presentations Annual & Quarterly Reports
  • Connect with Us

    Contact Us
    Email Us Biora Therapeutics Linkedin Biora Therapeutics Twitter
Privacy & Terms of Use Accessibility

© 2023 Biora Therapeutics, Inc. All rights reserved. Biora Therapeutics, NaviCap, BioJet, and GITrac are trademarks of Biora Therapeutics, Inc.

Precaution: investigational drug/device combination products. Currently limited by Federal law to investigational use only. Not for sale in the U.S.